Profile data is unavailable for this security.
About the company
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
- Revenue in CAD (TTM)0.00
- Net income in CAD-1.70m
- Incorporated2014
- Employees--
- LocationHemostemix Inc707 7th Ave. SW, Suite 1150CALGARY T2P 3H6CanadaCAN
- Phone+1 (905) 580-4170
- Fax+1 (403) 818-7672
- Websitehttps://hemostemix.com/